Value through Innovation27 July 2016

What is a lay summary?

Lay Summaries and Lay Summary Videos

  • TRADJENTA ® - Diabetes Mellitus, Type 2
    Clinical Study Number 1218.22
    Study Indication Diabetes Mellitus, Type 2
    Product TRADJENTA ®
    Generic Name Linagliptin
    Lab Code
    Clinical Phase IV
    Study Title

    A multicenter, international, randomized, parallel group, double-blind, placebo-controlled CArdiovascular Safety & Renal Microvascular outcomE study with LINAgliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk. CARMELINA

    Study Document
    Lay summary 1218.22 english